<DOC>
	<DOCNO>NCT01213732</DOCNO>
	<brief_summary>In study recombinant human fusion protein L19TNFα associate ILP standard treatment melphalan 10mg/l limb volume subject affect stage III/IV limb melanoma . The recombinant human fusion protein L19TNFα create intention target TNFα directly tumor tissue result high sustain intralesional bioactive TNFα concentration .</brief_summary>
	<brief_title>Phase 1 Dose-finding Study L19TNFα Plus Melphalan Using Isolated Inferior Limb Perfusion ( ILP ) Subjects With Intransit Stage III/IV Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>1 . Subjects age &gt; 18 year . 2 . Histologically cytologically confirm intransit stage III/IV melanoma low extremity distal apex femoral triangle 3 . ECOG performance status ≤ 2 . 4 . Subjects must least one unidimensional clinically measurable lesion define RECIST criterion ( see Section 8 ) . This lesion must irradiate within four week previous treatment . 5 . Absolute neutrophil count ( ANC ) ≥ 1.5 x 109/L , platelet ≥ 100 x 109/L , haemoglobin ( Hb ) ≥ 9.5 g/dl . 6 . All acute adverse effect ( exclude alopecia ) prior therapy ( include surgery , radiation therapy , chemotherapy ) must resolve ≤ Grade 1 , except elevate liver transaminase judge associated tumor infiltration ( see ) ( grade accord National Cancer Institute [ NCI ] Common Terminology Criteria Adverse Events , version 3.0 [ CTCAE , v.3.0 ] . 7 . Alkaline phosphatase ( AP ) , alanine aminotransferase ( ALT ) and/or aspartate aminotransferase ( AST ) ≤ 2.5 x upper limit normal ( ULN ) , total bilirubin ≤ 2.0 mg/dL unless liver involvement tumor , case transaminase level 5 x ULN allow . 8 . Creatinine ≤ 1.5 ULN 24 h creatinine clearance ≥ 60 mL/min . 9 . Testing negative acute chronic infection hepatitis B C virus , human immunodeficiency virus 1 2 . 10 . Negative pregnancy test female childbearing potential screening visit . 11 . Commitment subject practice medically appropriate/acceptable method birth control ( e.g. , hormonal , condoms adequate barrier control , intrauterine contraceptive device , sterilization ) begin screen visit continue 3 month follow treatment study drug 12 . Able provide write Informed Consent 13 . Willingness ability comply schedule visit , treatment plan , laboratory test study procedure . 1 . Breastfeeding woman 2 . Presence active infection ( e.g . require antimicrobial therapy ) severe concurrent disease , , opinion Investigator , would place subject undue risk interfere study . 3 . Active autoimmune disease . 4 . Cardiac disease manifest follow : &gt; Grade II heart failure , grade per New York Heart Association ( NYHA ) criterion . Unstable angina pectoris Acute subacute coronary syndrome , include myocardial infarction , occur 1 year prior study treatment Arrhythmia need continuous treatment Ejection fraction less institutional low limit normal assess multigated radionuclide angiography ( MUGA ) scan echocardiogram 5 . Uncontrolled hypertension . 6 . History claudication Ischemic peripheral vascular disease ( Grade IIbIV ) . 7 . Chronic obstructive pulmonary disease chronic pulmonary disease PFTs le 50 % predicted age . 8 . Symptomatic cerebrovascular disease . 9 . Active peptic ulcer disease . 10 . Concurrent infection HIV . 11 . Severe diabetic retinopathy . 12 . Major surgery trauma within 4 week prior start study treatment . 13 . Hypersensitivity melphalan TNFα intravenously administer human proteins/peptides/antibodies . 14 . Chemotherapy , radiation therapy therapy investigational agent within 4 week prior start study treatment . 15 . Any regional therapy affect extremity within 2 month prior start study treatment . 16 . Previous vivo exposure monoclonal antibody biological therapy 6 week administration study treatment . 17 . Growth factor immunomodulatory agent within 7 day prior administration study treatment . 18 . Subject require take corticosteroid immunosuppressant drug longterm basis . Limited use corticosteroid treat prevent acute hypersensitivity reaction consider exclusion criterion . 19 . Participation another interventional clinical trial participation trial . 20 . Any condition opinion Investigator could hamper compliance study protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>L19 , antibody , monoclonal , tumor targeting , TNFa , ILP , melanoma</keyword>
</DOC>